InvisiDerm’s new D’Oxyva™ therapy delivers health, beauty, and performance “from the inside out”
Pasadena, CA (PRWEB) August 31, 2011
(Read article on PRWeb.com: http://www.prweb.com/releases/2011/8/prweb8759621.htm)
InvisiDerm Healthcare (“InvisiDerm” or “the Company”), an emerging developer and manufacturer of novel transdermal drug delivery (TDD) methods, has recently begun placing its groundbreaking oxygen therapy delivery device, D’Oxyva™, in spas and wellness facilities throughout the United States and in several countries in Europe, Asia and the Middle East.
D’Oxyva™ provides spa clients with a much-needed boost in energy, balance, rejuvenation, and skin health that is aided by the unmatched blood flow increase D’Oxyva™ has demonstrated in pilot tests. The patent-pending D’Oxyva™ functions by delivering pure molecular carbon dioxide (CO2) to the bloodstream through the skin’s pores and sweat glands, free of needles, pressure, pain, and side effects.
Via a well-known and vital biological mechanism present in all humans called the Bohr Effect, the CO2 signals the blood cells to deliver additional molecular oxygen where it is most needed. The result is highly increased micro vessel blood flow, which delivers greater levels of oxygen to provide support and detoxification for many bodily processes.
The treatment requires nothing more than inserting a thumb into the D’Oxyva™ device for five minutes, and it is completely noninvasive. Unlike other well-known therapies such as Hyperbaric Oxygen Therapy and Carboxytherapy, D’Oxyva’s regenerative therapy is more effective because it works in conjunction with the body’s processes, rather than attempting to force external agents into the system.
The benefits of restoring healthy blood flow are undeniable, and InvisiDerm is poised to play a major role in making it a reality. In before-and-after pilot testing using a well-established US FDA-approved skin perfusion pressure measuring instrument attached to the big toe, researchers recorded increases in patient blood flow of over 100% with the application of a single D’Oxyva treatment.
Speaking of the pilot test results, InvisiDerm CEO Norbert Kiss stated, “The blood flow improvements we have seen with D’Oxyva are extremely rewarding to our team, as they demonstrate exactly what we have been working toward for years. Our technology is being enthusiastically embraced by the spa and wellness community, which we anticipate will make it available to a large part of the population in the near future.”
InvisiDerm has launched a full clinical test on D’Oxyva™ and anticipates having the results in the near future.
D’Oxyva™ is making inroads into spas and wellness facilities of all sizes, and InvisiDerm encourages people to seek one out and check out the blood flow improvements for themselves. Several noninvasive Laser Doppler-based measuring devices are available that can be easily used in conjunction with D’Oxyva for those wishing to record a quantitative picture of their own blood flow.
One of the featured locations for D’Oxyva™ treatments is Katie Raber’s Face & Body Esthetiques in Huntington Beach, California. Speaking of D’Oxyva™, Proprietor Katie Raber commented, “We are excited to be one of the first facilities to offer D’Oxyva™ treatments, helping our clients boost blood flow and generate great results for their health, wellness, and beauty.”
About InvisiDerm Healthcare (http://www.MyInvisiDerm.info) InvisiDerm, LLC, d/b/a/ InvisiDerm Healthcare, is an early stage medical device company in the United States that designs, develops, manufactures and markets groundbreaking, proprietary, truly noninvasive, and highly portable medical gas-powered transdermal delivery devices and accessories made in the USA. The Company has started manufacturing and marketing its initial product line in 2011, using its D’Oxyva™ oxygen therapy platform to target the spa, health-and–beauty, and anti-aging markets. More broadly, InvisiDerm is aiming to make hypodermic needle drug delivery obsolete and rapidly revolutionize the double-digit growth, multi-billion dollar transdermal drug delivery (TDD) industry with its next-generation products. The Company is a spin-out of The NKGroup and is headquartered in Pasadena, California.
Forward-Looking Information This press release may contain “forward-looking information”. This forward-looking information includes, or may be based upon, estimates, forecasts, and statements as to management’s expectations with respect to, among other things, the quality of the products of InvisiDerm Healthcare, its resources, progress in development, and demand and market outlook for noninvasive transdermal delivery medical devices in general. Forward-looking information is based on the opinions and estimates of management at the date the information is given, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include the inherent risks involved in the launch of a new medical device, the uncertainties involved in innovation and market acceptance, fluctuating component and other raw and advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and InvisiDerm Healthcare assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. InvisiDerm Healthcare makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.
For More Information Please visit http://www.MyInvisiDerm.info and send your general inquiries via the Contact Us page, or for specific inquiries contact InvisiDerm Public Relations at pr(at)myinvisiderm(dot)info or by phone at +1 (626) 817-6685.